期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 883, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2020.173366
关键词
Diosmetin; CML; SKP2; Bcr-Abl; Apoptosis
资金
- National Natural Science Foundation of China [81670156, 81773213]
- Natural Science Foundation research team of Guangdong Province [2018B030312001]
- Innovative Academic Team of Guangzhou Education System [1201610014]
- Research Team of Department of Education of Guangdong Province [2017KCXTD027]
- Guangzhou key medical discipline construction project fund
Bcr-Abl is the primary cause as well as currently key therapeutic target of chronic myeloid leukemia (CML). SKP2, an E3 ligase, is a downstream factor of Bcr-Abl to motivate the cell cycle transition of CML and also found to bind and activate Bcr-Abl in reverse. Therefore, SKP2/Bcr-Abl pathway is an attractive target for CML treatment. This study aims to identify an inhibitor of the SKP2/Bcr-Abl pathway based on a large screening of the natural products. We demonstrate that Diosmetin, a kind of phytoestrogens, notably downregulates the expression of SKP2, Bcr-Abl phosphorylation, and moderately downregulates the Bcr-Abl level. Furthermore, Diosmetin displays a favorable anti-tumor activity in CML cells and xenograft models. Collectively, our study reveals a natural compound in the treatment of CML on the basis of SKP2/Bcr-Abl signaling pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据